This Week in Gastroenterology — Jul 16, 2026

Welcome to This Week in Gastroenterology. This week we're covering eight notable papers spanning advanced therapeutics and clinical trial frameworks in inflammatory bowel disease, novel diagnostic and prognostic models in hepatology, and updated clinical guidance in endoscopy and pancreatology. Let's dive in.

We begin in the field of inflammatory bowel disease, where targeting tumor necrosis factor-like cytokine 1A, or TL1A, represents one of the most highly anticipated therapeutic pathways. In two parallel phase 2b randomized controlled trials published in The Lancet Gastroenterology and Hepatology, investigators evaluated the efficacy and safety of duvakitug, a novel anti-TL1A monoclonal antibody, in patients with moderately to severely active disease. The first trial, known as the RELIEVE UCCD study, randomized one hundred and thirty-seven adults with ulcerative colitis to receive either a high loading dose of duvakitug followed by maintenance doses of four hundred and fifty milligrams or nine hundred milligrams every two weeks, or a placebo [1]. Using a Bayesian statistical framework, the investigators set a success threshold where the posterior probability of superiority to placebo had to reach ninety percent or greater. At week fourteen, clinical remission was achieved by thirty-six percent of patients in the four hundred and fifty milligram group and forty-eight percent of patients in the nine hundred milligram group, compared to just twenty percent in the placebo group. This translated to posterior probabilities of superiority of ninety-five percent and over ninety-nine percent, respectively, easily exceeding the efficacy threshold. Crucially, about thirty-one percent of these patients had prior exposure to approved advanced therapies, and the safety profile of duvakitug was highly reassuring, with adverse event rates comparable to placebo and no new safety signals.

In the sister trial published in the same issue of The Lancet Gastroenterology and Hepatology, the investigators evaluated duvakitug using the exact same dosing regimens in one hundred and thirty-nine patients with moderately to severely active Crohn's disease, of whom fifty-seven percent had previously failed at least one advanced therapy [2]. For this trial, the primary endpoint was endoscopic response at week fourteen, defined as at least a fifty percent reduction in the Simple Endoscopic Score for Crohn's Disease. The results mirrored the ulcerative colitis trial, with twenty-six percent of patients in the four hundred and fifty milligram group and forty-eight percent in the nine hundred milligram group achieving an endoscopic response, compared to thirteen percent in the placebo group. The posterior probability of superiority was ninety-four percent for the lower dose and over ninety-nine percent for the higher dose. Together, these trials establish duvakitug as a potent therapeutic option that can achieve both clinical and objective endoscopic endpoints within a short fourteen-week timeframe. As we look to the future of inflammatory bowel disease therapeutics, the clinical focus is shifting from simple mucosal healing to the restoration of the intestinal epithelial barrier. Writing in Gut, an international panel of twelve specialists established the first consensus framework to guide the design of future clinical trials evaluating therapies that target intestinal barrier integrity and function [7]. Through a modified Delphi process, the panel achieved consensus on fourteen key statements. They recommend that intestinal barrier assessment be integrated as a formal trial endpoint, outlining specific guidance on the timing of reassessments, protocol requirements, and the standardization of tools such as imaging-based techniques, functional permeability assays, and endogenous biomarkers. This consensus provides a critical roadmap for the next generation of inflammatory bowel disease clinical trials.

Next, we turn to hepatology, where risk stratification and the identification of progressive silent diseases remain a clinical priority. In patients with compensated advanced chronic liver disease, the hepatic venous pressure gradient is the gold standard for predicting first decompensation, but its invasive nature limits widespread clinical use. To address this, a study published in the Journal of Hepatology developed and validated the Cirrhosis Risk Identifier, or CIRI, model [4]. CIRI is a machine-learning tool that utilizes eleven demographic and routine laboratory parameters to predict a patient's risk of first decompensation, which includes ascites, encephalopathy, and variceal bleeding. Trained on over one hundred and twelve thousand patients in the United States Optum Clinformatics Data Mart and externally validated in a prospective European cohort, the CIRI model demonstrated excellent prognostic performance. Its time-dependent area under the receiver operating characteristic curve was over point-eight-one, which was significantly superior to widely used non-invasive markers like FIB-4 and MELD, and comparable to the invasive hepatic venous pressure gradient itself. A CIRI score cutoff of negative eight point two five identified patients with a decompensation risk equivalent to a hepatic venous pressure gradient of ten millimeters of mercury or higher, representing clinically significant portal hypertension. This non-invasive, scalable tool could significantly improve our ability to identify high-risk patients and tailor surveillance intensity.

While risk stratification is improving in advanced disease, identifying progressive disease in its earlier stages is equally vital, particularly in patients who do not fit traditional metabolic profiles. A study published in Gut investigated the clinical features and long-term outcomes of cryptogenic steatotic liver disease, operationally defined as lean steatotic liver disease without any recorded cardiometabolic risk factors [6]. Analyzing over thirty thousand participants in the UK Biobank who underwent magnetic resonance proton density fat fraction imaging, the investigators found that non-obese individuals made up over three percent of the cohort, and of these, nearly fourteen percent met the criteria for cryptogenic steatotic liver disease. Despite having no recorded cardiometabolic risk factors, these patients exhibited less favorable metabolic and liver-related profiles, higher rates of advanced fibrosis, and a higher prevalence of the PNPLA3 and TM6SF2 genetic risk variants. Most alarmingly, longitudinal analysis from the Korean National Health Insurance Service cohort revealed that cryptogenic steatotic liver disease was associated with a two-and-a-half times higher risk of liver-related mortality, an association that persisted even after strict exclusion of alcohol use. This highlights that lean patients without metabolic risk factors are not immune to progressive liver disease and warrant close clinical attention. For patients whose liver disease has already progressed to advanced hepatocellular carcinoma, therapeutic options are historically limited. In a first-in-human phase one trial published in Nature, researchers evaluated C-CAR031, a novel glypican-3-specific chimeric antigen receptor T-cell therapy engineered with a dominant-negative transforming growth factor-beta receptor II to overcome the immunosuppressive tumor microenvironment [8]. Among thirty-six heavily pretreated patients with advanced hepatocellular carcinoma, the therapy demonstrated encouraging antitumor activity, with an objective response rate of forty-four percent and a median overall survival of over fourteen months. Although cytokine release syndrome was common, occurring in thirty-four patients, only two cases were severe, suggesting a manageable safety profile for this highly refractory patient population.

Finally, we examine key updates in endoscopy and pancreatology. While computer-aided detection systems have been shown to significantly improve adenoma detection rates in average-risk colorectal cancer screening, their utility in high-risk populations has been less clear. The CADLY2 trial, published in The Lancet Gastroenterology and Hepatology, was an international, multicenter, randomized controlled superiority trial designed to evaluate whether computer-aided detection improves the adenoma detection rate during Lynch syndrome surveillance [3]. Seven hundred and thirty-three patients with genetically confirmed Lynch syndrome were randomized to undergo either standard high-definition white-light colonoscopy alone or with the assistance of a computer-aided detection system. Surprisingly, the addition of artificial intelligence did not lead to a statistically significant improvement in the adenoma detection rate, which was thirty-one percent in the standard group compared to thirty-four percent in the artificial intelligence-assisted group. While the secondary evaluation of computer-aided optical diagnosis for differentiating neoplastic from non-neoplastic lesions showed a high sensitivity of eighty-six percent and a specificity of ninety-one percent, the primary trial findings suggest that artificial intelligence assistance does not provide the same added value in Lynch syndrome surveillance as it does in average-risk screening. Moving from the colon to the pancreas, there has been a growing clinical interest in intrapancreatic fat deposition and its association with pancreatitis, pancreatic cancer, and type two diabetes. To address the lack of a standardized clinical framework, twenty-five international experts developed the Melbourne consensus, published in Nature Reviews Gastroenterology and Hepatology [5]. The consensus formally defines fatty pancreas disorder as a distinct pathological state characterized by excessive intrapancreatic fat deposition that poses a health risk. The experts recommend magnetic resonance imaging as the gold standard for assessment and establish diagnostic criteria to classify the disorder into Type 1, which occurs in individuals without excess body fat mass, and Type 2, which occurs in those with excess body fat mass, providing a foundational framework for future clinical research and personalized preventive strategies.

If you only have time for one paper this week, make it the phase 2b trial of duvakitug in patients with ulcerative colitis, published in The Lancet Gastroenterology and Hepatology [1]. This study provides robust, phase 2b evidence for the efficacy of anti-TL1A therapy in achieving clinical remission, signaling a highly promising new therapeutic class for our moderate-to-severe ulcerative colitis patients.

Here are the key takeaways from this week in Gastroenterology. First, the anti-TL1A monoclonal antibody duvakitug demonstrated substantial efficacy in phase 2b trials, achieving significant clinical remission in ulcerative colitis and endoscopic response in Crohn's disease with a reassuring safety profile. Second, the machine-learning-based CIRI model offers a highly accurate, non-invasive alternative to hepatic venous pressure gradient measurements for predicting the risk of first hepatic decompensation in patients with compensated advanced chronic liver disease. Third, cryptogenic steatotic liver disease in lean individuals without traditional metabolic risk factors is a progressive phenotype associated with genetic risk variants, advanced fibrosis, and a significantly elevated risk of liver-related mortality. Fourth, computer-aided detection does not significantly improve adenoma detection rates during Lynch syndrome surveillance, indicating that standard high-definition white-light colonoscopy remains the clinical standard. Finally, the Melbourne consensus has formally defined fatty pancreas disorder as a distinct pathological entity, establishing magnetic resonance imaging as the preferred diagnostic modality and classifying the disease based on the presence or absence of excess body fat.

That's your roundup for This Week in Gastroenterology. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And for audio briefings on your own clinical questions and papers, visit audioscholar dot C C.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.